For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251202:nRSB7853Ja&default-theme=true
RNS Number : 7853J CVS Group plc 02 December 2025
02 December 2025
CVS GROUP plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")
Transaction in own shares
CVS announces that on 01 December 2025 it purchased the following number of
its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg,
Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the
terms of the share buyback programme announced on 24 October 2025 (the "Share
Buyback Programme").
Date of purchase: 01/12/2025
Aggregate number of Ordinary Shares purchased: 24,380
Lowest price paid per share (GBp): 1,216.00
Highest price paid per share (GBp): 1,230.00
Volume weighted average price paid per share (GBp): 1,221.26
CVS intends to cancel all of the purchased Ordinary Shares.
Following settlement of the above purchases and cancellation of the Ordinary
Shares purchased, CVS will have 71,038,131 Ordinary Shares in issue and holds
no Ordinary Shares in treasury.
The total number of voting rights in CVS is therefore 71,038,131 and this
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, CVS under the Financial Conduct Authority's
Disclosure and Transparency Rules.
Since the commencement of the Share Buyback Programme, the Company has
repurchased 702,652 Ordinary Shares in aggregate at a weighted average price
of 1,215.70 pence per share.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market
Abuse Regulation), as it forms part of Retained EU Law as defined in the
European Union (Withdrawal) Act 2018, the table below contains detailed
information of the individual trades made by Berenberg as part of the Share
Buyback Programme.
Individual transactions:
Number of Transaction price (GBp share) Time of Transaction Trading Venue
Ordinary Shares purchased transaction (UK Time) reference number
460 1220 01/12/2025 08:18:20 1343423437085083 XLON
577 1218 01/12/2025 08:30:00 1343423437086574 XLON
257 1218 01/12/2025 09:02:05 1343423437089975 XLON
803 1220 01/12/2025 09:35:00 1343423437093273 XLON
288 1220 01/12/2025 09:36:11 1343423437093342 XLON
219 1220 01/12/2025 09:36:11 1343423437093343 XLON
331 1218 01/12/2025 09:43:40 1343423437093795 XLON
436 1218 01/12/2025 09:55:18 1343423437094684 XLON
112 1218 01/12/2025 09:56:01 1343423437094744 XLON
662 1222 01/12/2025 10:42:12 1343423437097500 XLON
94 1222 01/12/2025 10:42:12 1343423437097501 XLON
577 1220 01/12/2025 10:47:30 1343423437097853 XLON
120 1220 01/12/2025 10:47:33 1343423437097854 XLON
248 1220 01/12/2025 10:53:56 1343423437098182 XLON
294 1216 01/12/2025 10:54:06 1343423437098186 XLON
179 1216 01/12/2025 10:54:06 1343423437098187 XLON
735 1218 01/12/2025 11:05:05 1343423437098948 XLON
257 1218 01/12/2025 11:05:05 1343423437098950 XLON
478 1218 01/12/2025 11:05:05 1343423437098951 XLON
732 1218 01/12/2025 11:06:54 1343423437099051 XLON
732 1220 01/12/2025 11:13:09 1343423437099505 XLON
71 1218 01/12/2025 11:13:15 1343423437099509 XLON
71 1218 01/12/2025 11:13:21 1343423437099513 XLON
560 1220 01/12/2025 11:21:06 1343423437100114 XLON
771 1224 01/12/2025 12:05:48 1343423437103984 XLON
131 1222 01/12/2025 12:31:53 1343423437105501 XLON
80 1222 01/12/2025 12:31:53 1343423437105502 XLON
816 1220 01/12/2025 12:55:00 1343423437107024 XLON
826 1220 01/12/2025 12:55:00 1343423437107032 XLON
826 1218 01/12/2025 12:55:47 1343423437107085 XLON
71 1218 01/12/2025 13:01:19 1343423437107463 XLON
288 1224 01/12/2025 13:18:04 1343423437108804 XLON
200 1222 01/12/2025 13:45:07 1343423437111282 XLON
400 1222 01/12/2025 13:45:08 1343423437111283 XLON
41 1220 01/12/2025 13:50:26 1343423437111694 XLON
922 1220 01/12/2025 13:50:26 1343423437111695 XLON
200 1218 01/12/2025 13:50:32 1343423437111709 XLON
200 1218 01/12/2025 13:51:03 1343423437111754 XLON
971 1216 01/12/2025 13:52:00 1343423437111856 XLON
995 1216 01/12/2025 13:52:00 1343423437111857 XLON
559 1218 01/12/2025 13:52:58 1343423437111941 XLON
158 1218 01/12/2025 13:52:58 1343423437111942 XLON
1161 1220 01/12/2025 13:54:42 1343423437112080 XLON
653 1230 01/12/2025 15:34:26 1343423437128374 XLON
1 1230 01/12/2025 15:34:26 1343423437128375 XLON
64 1230 01/12/2025 15:34:31 1343423437128382 XLON
11 1230 01/12/2025 15:34:31 1343423437128383 XLON
1187 1228 01/12/2025 15:50:19 1343423437131054 XLON
84 1228 01/12/2025 15:50:21 1343423437131064 XLON
50 1228 01/12/2025 15:50:21 1343423437131065 XLON
7 1228 01/12/2025 15:50:21 1343423437131066 XLON
306 1228 01/12/2025 15:50:23 1343423437131070 XLON
330 1228 01/12/2025 15:59:41 1343423437132940 XLON
103 1228 01/12/2025 15:59:41 1343423437132945 XLON
111 1228 01/12/2025 15:59:41 1343423437132944 XLON
119 1228 01/12/2025 15:59:41 1343423437132943 XLON
158 1228 01/12/2025 15:59:41 1343423437132942 XLON
119 1228 01/12/2025 15:59:41 1343423437132941 XLON
8 1228 01/12/2025 16:01:24 1343423437133540 XLON
96 1228 01/12/2025 16:08:02 1343423437134985 XLON
191 1228 01/12/2025 16:08:02 1343423437134984 XLON
313 1228 01/12/2025 16:09:03 1343423437135203 XLON
199 1228 01/12/2025 16:09:03 1343423437135206 XLON
471 1228 01/12/2025 16:09:03 1343423437135204 XLON
24 1228 01/12/2025 16:09:03 1343423437135207 XLON
175 1228 01/12/2025 16:09:09 1343423437135224 XLON
270 1228 01/12/2025 16:15:03 1343423437136545 XLON
421 1228 01/12/2025 16:15:03 1343423437136546 XLON
Contacts
CVS Group
plc
via Camarco
Richard Fairman, CEO
Robin Alfonso, CFO
Paul Higgs, Chief Veterinary Officer
Charlotte Page, Head of Investor Relations
Peel Hunt LLP (Nominated Adviser & Joint
Broker)
+44 (0)20 7418 8900
Christopher Golden / James Steel / Andrew Clark
Berenberg (Joint Broker)
+44 (0)20 3207 7800
Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing
Camarco (Financial PR)
cvsg@camarco.co.uk
Ginny Pulbrook
+44
(0)7961 315 138
Letaba Rimell
Tilly Butcher
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is an AIM-listed provider of veterinary services with operations in
the UK and Australia. CVS is focused on providing high-quality clinical
services to its clients and their animals, with outstanding and dedicated
clinical teams and support colleagues at the core of its strategy.
The Group now operates c.470 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").
The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and
c.3,300 nurses.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSUPGPCPUPAPWG
Copyright 2019 Regulatory News Service, all rights reserved